Table 1 Selected RCTs for systemic chemotherapy of advanced colorectal cancer
Author, year | Pat. [n] | Treatment regimen | Median PFS [months] | Median OS [months] |
|---|---|---|---|---|
DeGramont, 2000 [15] | 210 | FOLFOX4 | 9.0 | 16.2 |
Giacchetti, 2000 [16] | 100 | FOLFOX | 8.7 | 19.4 |
Douillard, 2000 [17] | 199 | FOLFIRI | 6.7 | 17.4 |
Saltz, 2000 [18] | 226 | IFL | 7.0 | 14.8 |
Tournigand, 2003 [19] | 109 | FOLFIRI/FOLFOX6 | 14.2 | 21.5 |
Hurwitz, 2004 [20] | 402 | IFL/bevacizumab | 10.6 | 20.3 |
Goldberg, 2006 [21] | 154 | FOLFOX4 | 9.7 | 19.0 |
Falcone, 2007 [13] | 122 | FOLFOXIRI | 9.8 | 22.6 |
57 | FOLFIRI/bevacizumab | 11.2 | 28.0 | |
Saltz, 2008 [24] | 699 | FOLFOX4/bevacizumab | 9.4 | 21.3 |
Hecht, 2009 [25] | 823 | FOLFOX/FOLFIRI/bev | 11.4 | 24.5 |
| Â | Â | + panitumumab | 10.0 | 19.4 |
Tebbutt, 2010 [26] | 157 | capecitabine/bevacizumab | 8.5 | - |
Stathopoulos, 2010 [27] | 114 | IRI/5-FU/FA/bevacizumab | - | 22.0 |
| Â | 108 | IRI/5-FU/FA | - | 25.0 |
Douillard, 2010 [28] | 1183 | FOLFOX4/panitumumab | 9.6 | 23.9 |